Another cancer-specific monoclone Ab (casmab) against human Pdpn was shown to react with Pdpn-expressing cancer cells but not normal cells, which is expected to be helpful for molecular targeting therapy against Pdpn-expressing cancers (Kato and Kaneko, 2014). Here, PDPN is linked to cancer.